Anxiety treatment
Coaching vs recommendations in IntelliCare
Open access · cc by · source: Europe PMC
In a factorial RCT, coaching lowered anxiety more than self-guided use, while weekly app recommendations boosted depression improvement and app sessions.
Study at a glance
- Design
- RCT — 2×2 factorial: coaching vs self-guided × weekly app recommendations vs none
- N
- N=301 · Adults with elevated PHQ-9 or GAD-7 using IntelliCare suite
- Population
- Adults with elevated depression or anxiety symptoms using IntelliCare Android apps
- Outcome
- PHQ-9/GAD-7 change and app engagement over ~8 weeks
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
PHQ-9 and GAD-7 fell significantly over time across arms. Coaching produced larger GAD-7 reductions than self-guided care; recommendations interacted with time to strengthen PHQ-9 gains and raised median app sessions. Engagement was high (median 216 sessions; median last use day 56).
Methodology
Adults with elevated PHQ-9 or GAD-7 scores used the IntelliCare Android app suite in a 2×2 factorial randomized trial crossing human coaching versus self-guided use with weekly app recommendations versus none. Engagement and symptom outcomes were tracked over about 8 weeks.
Limitations
Effects are platform-specific to IntelliCare Android users meeting symptom thresholds. Follow-up loss differed by cell, and coaching did not clearly beat self-guidance on depression. Results do not identify which individual mini-apps drive benefit.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Multiple studies in this library examine anxiety treatment with empirical patient or population outcomes rather than opinion alone.
Evidence for the claim as stated.
PHQ-9 and GAD-7 fell significantly over time across arms. Coaching produced larger GAD-7 reductions than self-guided care; recommendations interacted with time to strengthen PHQ-9 gains and raised median app sessions. Engagement was high (median 216 sessions; median last use day 56).
Evidence for the claim as stated.
Effect sizes and settings differ across anxiety treatment studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
Evidence for the claim as stated.
IntelliCare used PHQ-9 both to enter and to judge outcome. A single-arm field trial of 105 adults (PHQ-9 ≥10 and/or GAD-7 ≥8) found significant paired-score improvement, with 37% reaching PHQ-9 <5 and 42% GAD-7 <5 by end of treatment. A later 2×2 factorial RCT found PHQ-9 and GAD-7 fell across arms; coaching produced larger GAD-7 reductions than self-guided care, while weekly recommendations strengthened PHQ-9 gains and raised median sessions (median 216; last use day 56). Coaching did not clearly beat self-guidance on depression.
Evidence for the claim as stated.
PHQ-9 and GAD-7 do not always move as a pair, and not every digital support changes either. IntelliCare coaching favoured GAD-7 more than PHQ-9; iCBT moved both (g=0.78 and 0.72); the carer forum moved neither overall. Using PHQ-9 as the sole outcome would have missed the factorial trial's clearest coaching signal.
Evidence for the claim as stated.
Not every tagged paper plotted deaths. An IntelliCare 2×2 factorial RCT followed PHQ-9 and GAD-7 over about 8 weeks in adults above symptom thresholds; coaching favoured GAD-7, recommendations favoured PHQ-9, and engagement was high (median 216 sessions; median last use day 56). Those are symptom and usage trajectories, not Kaplan–Meier overall survival. Lexicon over-recruitment is why the paper sits in this method list.
Evidence for the claim as stated.
KM in a randomised anaesthetic trial, KM in a biomarker series, KM in a screening cohort, and an 8-week app RCT are not one method applied four times. Propofol versus sevoflurane can say assigned anaesthetic did not shift 5-year OS (~92%, HR near 1). ANXA1's HR 1.70 in HER2-positive overexpression is an observational 10-year BCSS association. NZ ethnic survival gaps change when the sample is restricted to screen-detected cancers. IntelliCare did not analyse cancer death at all.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Effect sizes and settings differ across anxiety treatment studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
- Supports · Automated e-therapy for anxiety disorders
- Supports · IntelliCare app suite field trial
PHQ-9 and GAD-7 do not always move as a pair, and not every digital support changes either. IntelliCare coaching favoured GAD-7 more than PHQ-9; iCBT moved both (g=0.78 and 0.72); the carer forum moved neither overall. Using PHQ-9 as the sole outcome would have missed the factorial trial's clearest coaching signal.
- Supports · iCBT for depression in diabetes
- Supports · Dementia-carer internet support forum
KM in a randomised anaesthetic trial, KM in a biomarker series, KM in a screening cohort, and an 8-week app RCT are not one method applied four times. Propofol versus sevoflurane can say assigned anaesthetic did not shift 5-year OS (~92%, HR near 1). ANXA1's HR 1.70 in HER2-positive overexpression is an observational 10-year BCSS association. NZ ethnic survival gaps change when the sample is restricted to screen-detected cancers. IntelliCare did not analyse cancer death at all.
- Supports · Propofol vs sevoflurane and breast cancer survival
- Supports · ANXA1 in breast cancer prognosis
- Supports · Screening and breast cancer equity in NZ
Related papers in this topic
Same topic cluster — not a recommendation engine.